[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100078068":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":7,"locations":7,"responsibleParty":7,"collaborators":7,"id":16,"slug":17,"hasResults":18,"nctId":19,"briefTitle":20,"officialTitle":21,"acronym":7,"eligibilityCriteria":22,"healthyVolunteers":18,"sex":23,"minAge":24,"maxAge":7,"enrollmentInfo":25,"targetDuration":7,"studyType":28,"phases":29,"briefSummary":31,"conditions":32,"keywords":35,"overallStatus":40,"whyStopped":7,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":7},{"fullName":5,"class":6},"Scios, Inc.","INDUSTRY",null,[9],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":7},"DRUG","nesiritide",[13],{"name":14,"affiliation":5,"role":15},"Scios, Inc. Clinical Trial","STUDY_DIRECTOR","100078068","phase-3-a-study-to-develop-additional-safety-and-clinical-experience-with-natrecor-hbnp-nesiritide-in-the-treatment-of-patients-with-worsening-congestive-heart-failure-who-require-inpatient-intravenous-therapy-with-medications-that-influence-the-tone-and-caliber-of-blood-vessels-100078068",false,"NCT00271557","A Study to Develop Additional Safety and Clinical Experience With NATRECOR hBNP (Nesiritide) in the Treatment of Patients With Worsening Congestive Heart Failure Who Require Inpatient Intravenous Therapy With Medications That Influence the Tone and Caliber of Blood Vessels","A Randomized, Open-Label, Active-Controlled, Multicenter Phase III Safety Study of Two Doses of NATRECOR hBNP (Nesiritide) Administered as a Continuous Infusion in the Treatment of Decompensated CHF","Inclusion Criteria:\n\n* Patients with a previous history of chronic congestive heart failure (CHF)\n* presenting with symptomatic, decompensated CHF for inpatient intravenous therapy with medications that influence the tone and caliber of blood vessels (other than, or in addition to, diuretics)\n\nExclusion Criteria:\n\n* Patients with myocardial ischemia within the past 48 hours\n* having significant valvular stenosis, obstructive cardiomyopathy, constrictive pericarditis or primary pulmonary hypertension\n* being treated with intravenous (IV) therapy with medications that influence the tone and caliber of blood vessels for \\> 4 hours for this episode of CHF\n* already being treated with IV therapy with medications that influence the tone and caliber of blood vessels that cannot be discontinued\n* having cardiogenic shock, systolic blood pressure consistently \\\u003C 90 mm Hg or other significant blood circulation instability.","ALL","18 Years",{"count":26,"type":27},305,"ACTUAL","INTERVENTIONAL",[30],"PHASE3","The purpose of this safety study is to evaluate NATRECOR® hBNP (a recombinant form of the natural human peptide normally secreted by the heart in response to heart failure), in subjects with worsening congestive heart failure for whom inpatient intravenous therapy with medications that influence the tone and caliber of blood vessels is deemed appropriate.",[33,34],"Heart Failure, Congestive","Heart Decompensation",[36,37,38,34,39],"Heart Failure","Renal Dysfunction","Cardiomyopathy","Dyspnea Paroxysmal.","COMPLETED","2011-03-03",{"date":43,"type":44},"2011-03-04","ESTIMATED",{"date":46,"type":7},"1997-01",{"date":48,"type":27},"1997-12",{"name":5,"class":6}]